1， Shiraishi K, Hamano M*, Huili M*, Kawano K* Maitani Y*, Aoshi T**, Ishii KJ**, Yokoyama M (* Institute of Medicinal Chemistry, Hoshi University, **Immunology Frontier Research Center, Osaka University) Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon. J. Controlled Release 2013; 165: 183-190.
2, Sanada Y*, Akiba I*, Sakurai K*, Shiraishi K, Yokoyama M, Mylonas E**, Ohta N**, Yagi N**, ShinoharaY***, Amemiya Y*** (*Department of Chemistry and Biochemistry, The University of Kitakyushu, ** Japan Synchrotron Radiation Research Institute, *** Graduate School of Frontier Sciences, The University of Tokyo) Hydrophobic Molecules Infiltrating into the PEG Domain of the Core/Shell Interface of a Polymeric Micelle: Evidence Obtained with Anomalous Small-Angle X-ray Scattering. Journal of the American Chemical Society 2013; 135: 2574-82.
3, Shiraishi K, Harada Y*, Kawano K**, Maitani Y**, Hori K***, Yanagihara K****, Takigahira M*****, and Yokoyama M (*Yokoyama “Nano-medical Polymer” Project, Kanagawa Academy of Science and Technology, ** Institute of Medicinal Chemistry, Hoshi University, *** Institute of Development Aging and Cancer, Tohoku University, **** Yasuda Woman’s University, Faculty of Pharmacy, ***** Central Animal Laboratory, National Cancer Center Research Institute). Tumor environment changed by combretastatin derivative (Cderiv) pretreatment that leads to effective tumor targeting, MRI studies and antitumor activity of polymeric micelle carrier systems, Pharmaceutical Research 2012; 29: 178–186.
4, Shiraishi K, Endoh R, Furuhata H, Nishihara M*, Suzuki R**, Maruyama K**, Oda Y**, Jo J***, Tabata Y***, Yamamoto J****, Yokoyama M (*Takahara Soft Interfaces Project, Japan Science and Technology Agency, ** School of Pharmaceutical Sciences, Teikyo University, ***Institute for Frontier Medical Sciences, Kyoto University, ****Division of Physics and Astronomy, Graduate School of Science, Kyoto University). A facile preparation method of a PFC-containing nano-sized emulsion for theranostics of solid tumors. International J Pharmaceutics 2011; 421: 379-87.
5, Harada Y*, Yamamoto T*, Sakai M**, Saiki T**, Kawano K***, Maitani Y***, Yokoyama M (*Yokoyama “Nano-medical Polymer” Project, Kanagawa Academy Science and Technology, **Near-Field Optics Group, Kanagawa Academy of Science and Technology, *** Institute of Medicinal Chemistry, Hoshi University). Effects of organic solvents on drug incorporation into polymeric carriers and morphological analyses of drug-incorporated polymeric micelles, International J Pharmaceutics 2011; 404: 271–280.
6, Shiraishi K, Kawano K*, Maitani Y*, Yokoyama M (*Inst Medicinal Chemistry, Hoshi University). Synthesis of Poly(ethylene glycol)-b-Poly(L-lysine) Block Copolymers Having Gd-DOTA as MRI Contrast Agent and Their Polymeric Micelle Formation by Polyion Complexation, J Controlled Release 2010; 148: 160-7
7, Hori K*, Nishihara M**, Yokoyama M (*Inst Development, Aging and Cancer, Tohoku University, ** Yokoyama “Nanomedical Polymer” Project, Kanagawa Academy of Science and Technology). The Combretastatin Derivative Cderiv, a Vascular Disrupting Agent, Enables Polymeric Nanomicelles to Accumulate in Microtumors, J Pharmaceutical Sciences 2010; 99: 2914-25.
8, Ma H*, Shiraishi K, Minowa T*, Kawano K*, Yokoyama M, Hattori Y*, Maitani Y* (*Inst Medicinal Chemistry, Hoshi University). Accelerated Blood Clearance Was Not Induced for a Gadolinium-Containing PEG-poly(L-lysine)-Based Polymeric Micelle in Mice, Pharmaceutical Research 2010; 27: 296-302.
9, Yokoyama M. Polymeric micelles as a novel drug carrier system and their required considerations for clinical trials. Expert Opinion on Drug Delivery 2010; 7: 145-58.
10, Minowa T*, Kawano K*, Kuribayashi H**, Shiraishi K, Sugino T***, Hattori Y*, Yokoyama M, Maitani Y* (*Inst Medicinal Chemistry, Hoshi University, **Varian Technologies Japan Limited, ***Dep. Basic Pathology, Fukushima Medical University). Increase in tumour permeability following TGF-b type I receptor inhibitor treatment observed by dynamic contrast-enhanced MRI. British J Cancer 2009; 101: 1884-1890.